Breaking News, Financial News

Eurand 1Q08

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Eurand 1Q Revenues: $24.9 million (+24%) 1Q Loss: $1.6 million (loss of $1.2 million in 1Q07) Comments: Product sales were $32.0 million (+17%). Royalties were $2.7 million (+103%). R&D expenses were $7.1 million (+21%). Revenues include $1.4 million from the Source CF acquisition....

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters